期刊文献+

舒洛地特对老年男性慢性肾病患者蛋白尿及安全性的影响 被引量:3

Efficacy and safety of sulodexide on proteinuria in elderly male patients with chronic kidney disease
下载PDF
导出
摘要 目的观察舒洛地特对老年男性慢性肾病患者蛋白尿的影响。方法将122例伴有蛋白尿的老年男性非透析慢性肾脏病患者根据24h尿蛋白定量分为轻度蛋白尿(A组54例,0.3g≤24h尿蛋白定量<1.5g),中度蛋白尿(B组40例,1.5g≤24h尿蛋白定量<3.5g),大量蛋白尿(C组28例,24h尿蛋白定量≥3.5g)。3组患者在慢性肾脏病常规治疗基础上,均给予舒洛地特600LSU治疗,1/d,疗程20d。比较3组治疗前、后24h尿蛋白定量、血清肌酐、尿素氮、尿酸和凝血功能等指标变化。结果24h尿蛋白定量A组、B组治疗前、后比较,差异有统计学意义(P<0.01),C组无显著变化(P>0.05)。血清肌酐、尿素氮和尿酸3组治疗前、后比较,差异均无统计学意义(P>0.05)。血浆凝血酶原时间、凝血酶时间、活化部分凝血酶原时间和纤维蛋白原3组患者治疗前、后比较,差异有统计学意义(P<0.05)。结论舒洛地特可降低非大量蛋白尿的老年男性患者的慢性肾脏病尿蛋白水平及凝血功能,对肾功能无明显影响。 Objective To observe efficacy of sulodexide on proteinuria in elderly male patients with chronic kidney disease(CKD).Methods One hundred and twenty-two non-dialysis CKD elderly male patients were enrolled.They were divided into 3 groups according to the levels of 24h proteinuria: group A(0.3g≤24h proteinuria1.5g),group B(1.5g≤24h proteinuria3.5g) and group C(24h proteinuria≥3.5g).All groups were given routine treatment and sulodexide 600 LSU/d for 20 days.Quantization of 24h proteinuria,serum creatinine(Scr),blood urea nitrogen(Bun),uric acid(UA) and conventional blood coagulative parameters were analyzed in the three groups before and after treatment.Results In the group A and group B,the levels of 24h proteinuria were decreased significantly at the end of the treatment(P0.01).There were no changes in Scr,BUN and UA after 20 days treatment in all the three groups(P0.05).However the levels of prothrombin time(PT),thrombin time(TT)and activated partial thromboplastin time(APTT)were significantly increased(P0.01) and fibrinogen(FIB)was decreased(P0.05) at the end of the treatment in the three groups.Conclusions Sulodexide can lower level of proteinuria in elderly male CKD patients who are not macroproteinuria.There were no changes in renal function after treatment.
出处 《中华保健医学杂志》 2013年第2期92-95,共4页 Chinese Journal of Health Care and Medicine
基金 国家自然科学基金(30772296 81170312)
关键词 慢性肾病 舒洛地特 蛋白尿 chronic kidney disease sulodexide Proteinuria
  • 相关文献

参考文献12

  • 1Zhang L,Zhang P,Wang F,et al. Prevalence and factors associat- ed with CKD:a population study from Beijing [J]. Am J KidneyDis ,2008,51:373-384.
  • 2Turner JM,Bauer C,Abramowitz MK,et al. Treatment of chronic kidney disease[J]. Kidney International,2012,81:351-362.
  • 3Gaddi AV,Cicero AF,Gambaro G. Nephroprotective action of gly- cosaminoglycans why the pharmacological properties of sulodexide might be reconsidered [J]. Int J Nephrol Renovasc Dis,2010,3 : 99-105.
  • 4Shu J,Zeng LY,Lin KY,et al. Renal protective effects of su- lodexide in diabetic rats and its anti-oxidative mechanism [J]. Nan Fang Yi Ke Da Xue Xue Bao. 2009,29:778-780.
  • 5张颖娟,连耀国,夏文丽,李明喜,李雪梅,郑法雷.舒洛地特抑制单侧输尿管梗阻小鼠肾间质纤维化[J].北京医学,2011,33(2):157-162. 被引量:4
  • 6王颖,燕树勋.舒洛地特对老年高血压肾损害患者肾功能的影响[J].中国新药与临床杂志,2011,30(10):762-765. 被引量:4
  • 7Valocikov6 I. Sulodexid and nephrotic syndrome in patients with diabetic nephropathy [ J ]. Vnitr Lek, 2011,57 : 507-510.
  • 8Bang K,Chin HJ,Chae DW,et al. Anti-proteinuric effect ofsulodexide in imInunoglobulin a nephropathy [J]. Yonsei Med J, 2011,52:588-594.
  • 9Packham DK,Wolfe R,Reutens AT,et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic: nephropathy [J]. J Am Soc Nephrol,2012,23:123-130.
  • 10Pletinck A,Van Landschoot M,Steppan S,et al. Oral supple- mentation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion[J]. Nephrol Dial Transplant,2012, 27 : 548-556.

二级参考文献12

共引文献5

同被引文献49

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部